JW Holdings: 2026 Q1 Earnings and GLP-1 License-in Deal
Consolidated Q1 2026: revenue KRW 243.2B (+1.5% QoQ), operating profit KRW 51.5B (+23.3% QoQ), net income KRW 39.8B
Separate revenue KRW 20.5B (-25.5% YoY) due to lower dividend income
Post-report (Apr 8, 2026): subsidiary JW Pharmaceutical in-licensed GLP-1 drug Bofanglutide from Gan & Lee for obesity/diabetes (up to $81.1M, $5M upfront)
R&D pipeline: gout drug URC102 in global phase 3, cancer drug JW2286 in phase 1, hair loss drug JW0061 IND approved for phase 1
Acquired 100% of venture capital firm Soliderus Investment for KRW 30.6B in March 2026
Consolidated debt ratio 109% but cash & equivalents KRW 64.8B; paid KRW 14.9B in dividends